|Publication number||US4762720 A|
|Application number||US 06/777,675|
|Publication date||Aug 9, 1988|
|Filing date||Sep 19, 1985|
|Priority date||Sep 21, 1984|
|Also published as||EP0179237A1|
|Publication number||06777675, 777675, US 4762720 A, US 4762720A, US-A-4762720, US4762720 A, US4762720A|
|Original Assignee||Shionogi & Co., Ltd.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (1), Referenced by (64), Classifications (11), Legal Events (6)|
|External Links: USPTO, USPTO Assignment, Espacenet|
1. Field of the Invention
Vesicles, which are so-called "liposomes" consisting of phospholipid bilayers, can be prepared by dispersing a lipid in an aqueous solvent. The liposomes can be useful as a drug-carrier for the administration to subjects if a drug is contained in aqueous compartments in liposome. The present invention relates to processes for preparing liposome compositions containing clinically active ingredients.
2. Prior Art
A process to prepare liposome compositions is disclosed in JPN Unexam. Pat. Pub. No. 53-142514 where the liposome compositions which have been formulated with phospholipid, active ingredient, and adjuvants are freeze-dried for stable storage.
Processes to prepare highly safe liposome compositions are also disclosed in JPN Unexam. Pat. Pub. Nos. 57-82310 and 57-82311 where freeze-dried vesicles are prepared with no organic solvent and are formulated into liposome compositions by the use of an aqueous medium containing any active ingredient.
On the other hand, a process is disclosed in the JPN Unexam. Pat. Pub. No. 58-152812, wherein SUV (small unilamella vesicles) or LUV (large unilamella vesicles) are prepared by dispersing a special phospholipid in an aqueous medium having a specific pH-value.
A process for preparing liposome compositions which comprises dispersing freeze-dried MLV or SUV in an aqueous medium in the presence of both an active ingredient and a divalent cation to regenerate LUV or LOV (large oligolamella vesicle) entrapping said active ingredient.
A conventional manner for liposome formulation, i.e., hydration method gives only MLV (multilamella vesicles) which is constructed by multiple phospholipid layers and aqueous compartments unless the procedures are carried out under a specific condition, as shown in the JPN Unexam. Pat. Pub. No. 58-152812. When the lyophilizates of these MLV are dispersed in a brine or a buffer which is generally used as an aqueous medium, they are reformed into MLV. In the MLV, the rate of retention of aqueous medium per unit amount of phospholipid is smaller than in the LUV. The captured volume of MLV is, therefore, smaller and the up-take rate of an active ingredient into it is lower.
The present inventor has studied for the purpose of obtaining regenerated LUV or LOV, each of which has a large captured volume and a high uptake-rate of an active ingredient into itself when preparing liposome compositions by dispersing freeze-dried liposomes in an aqueous medium.
The present inventor has found that liposomes can be reformed into LUV or LOV when the lyophilizates of MLV or SUV are dispersed in an aqueous medium if a divalent cation is present in the aqueous medium within a specific range of the concentration. Prior to this invention, the present inventor had found that LUV or LOV is regenerated if the ionic strength of monovalent cation is kept at 0.05 or below in the regeneration procedures (JPN Pat. Appln. No. 59-171265). The fact means that LUV or LOV are never regenerated but MLV if the ionic strength is over 0.05. However in this invention, the presence of a specific amount of a divalent cation prevents the regeneration of MLV and gives desired LUV or LOV.
Lecithins, i.e., saturated or unsaturated phosphatidyl choline, which are lipids composing liposome, are employed for this invention. These lecithins may be combined with phosphatidyl serine, phosphatidyl ethanolamine, phosphatidyl inositol, diphosphatidyl glycolol, phosphatidate, sphingomyelin, or the like; and further with cholesterol or electrically charged substances (e.g., stearylamine, dicetylphosphate). The representatives of them are lecithins derived from yolk, soybean, or tissues of the other animals or plants, hydrogenates thereof, and synthetic lecithins, which may be employed solely or in a mixture of them. For instance, dipalmitoyl phosphatidylcholine, distearoyl phosphatidylcholine, 1-palmitoyl-2-stearoyl phosphatidylcholine, 1-stearoyl-2-palmitoyl phosphatidylcholine, and the like can be employed solely or in combination.
The freeze-dried liposomes employed in this invention are the freeze-dried MLV or SLV prepared by the known method, which may be obtained by means of any method for lyophilization.
Examples of the active ingredients entrapped are anticancer agents such as 5-fluorouracil, neomycin, bleomycin, or the like; antibiotic agents such as chloramphenicol, tetracycline, cefalexin, latamoxef, or the like; enzymes or homologues such as urokinase or the like; peptides such as interferon, interleukin, globulin, insulin or the like; nucleic acids such a DNA, RNA, or the like; vitamins; or the other agents such as sulfamethoxazole, phenobarbital, or the like.
The clinically active ingredients to be entrapped may be ○1 added to liposome dispersion system just before the freeze-drying or ○2 dispersed along with freeze-dried liposome: thus obtained mixture is dispersed in an aqueous medium containing a proper divalent cation to regenerate a liposome composition. Alternatively, the active ingredient may be ○3 dissolved or dispersed in the aqueous medium in which freeze-dried liposomes have been dispersed, whereby the freeze-dried liposomes are regenerated.
Water, brine (e.g., isotonic saline), buffer (e.g., phosphate buffer, trisaminomethane buffer) or the like is employed as an aqueous medium in which the freeze-dried liposomes are dispersed: the choice depends on the purposes for which the resulting liposome composition is used.
Divalent cation in this invention means metallic ion including calcium, magnesium, zinc, manganese, iron, cobalt, nickel, or the like; particularly, calcium, manganese, or magnesium gives significant effects. When freeze-dried SUV or MLV are dispersed in an aqueous medium containing divalent cation, they are reformed into LUV or LOV: the optimum concentration of the divalent cation varies with the sort of the metallic ion.
There is an optimum range of concentrations on each ion, for instance, the optimum range on calcium is about 3×10-3 to 1×10-1 M, about 4×10-3 to 1×10-1 M on magnesium, about 8×10-4 to 1×10-1 M on manganese: the sort of the metallic ions and their concentrations may be determined by the purpose of using liposome compositions.
When the freeze-dried liposomes prepared from synthetic lecithin are applied to regeneration according to the aforementioned disclosure JPN Pat. Appln. No. 59-171265, liposomes are not regenerated if the procedures are carried out below the gelphase/liquid crystal-phase transition temperature of the lecithin used. In order to accomplish this invention on the freeze-dried liposome, it should be noted that the system must be warmed up over said temperature.
Thus obtained liposome compositions may be orally or parenterally administered to subjects directly or in the state of the purified dispersion by removing the excessive active agent remaining outside the liposome by the method of centrifugal separation, ultrafiltration, gelfiltration, or the like.
The present invention is explained in more detail by the following examples, which do not limit the scope of this invention.
Commercially available yolk lecithin (made by Merck & Co.) was further refined by silica gel chromatography. Chloroform solution of 354 mg of the refined lecithin was placed in a 200 ml round-bottom flask and evaporated to dryness by a rotary evaporator to give a thin layer of the phospholipid on the inner wall of the flask. To the adequately dried layer was added a mixture (30 ml) of water with 1.5 parts of mannitol and the mixture was shaken with hands to prepare a dispersion of MLV. The dispersion was frozen with dry-ice/acetone and freeze-dried by a vacuum pump. 1% Aqueous human serum albumin (HSA) containing sodium chloride (NaCl 0.05M) and/or calcium chloride (CaCl2 0.03M) was added to the freeze-dried substance at a rate of 0.4 ml to 25 mg of the freeze-dried substance (10 mg as lecithin) at room temperature. The mixture was allowed to stand for an hour while being occasionally shaken, combined with 5 ml of an isotonic aqueous NaCl, and divided by means of ultra-cetrifugal separation (85,000 g×60 minutes) into the external solution and liposomes. The isolated liposomes were dispersed again in another 5 ml of said isotonic NaCl and centrifugally separated. By the quantitative analysis of HSA in the accumulative external solution, the up-take rate of HSA into liposomes on their regeneration were measured (Table 1).
Table 1 shows positive effect of calcium ion to and negative effect of sodium ion against the formation of liposomes having large captured volume.
HSA was quantitatively analyzed according to Lowry's method (Shin Jikken Kagaku-Koza 20-I, 130 published by Maruzen).
TABLE 1______________________________________ Uptake rate Captured Vol.*Ion (%) of HSA (μl/mg lipid)______________________________________1 None 37.3 12.42 0.03 M of CaCl2 45.1 15.53 0.05 M of NaCl 11.6 2.14 0.03 M CaCl2, 0.05 M NaCl 34.8 11.4______________________________________ *The value of the captured volume is free from HSA (6.2% to uptake rate) adsorbed on the liposome surfaces.
In the same manner as in Example 1, 262 mg of a hydrogenated yolk lecithin (iodine value 3, Asahi Chem. Ind.) were employed for the formation of the thin layer on the inner wall of a round-bottom flask. Purified water (20 ml) was added thereto to give a dispersion of MLV.
The dispersion was freeze-dried to leave powder. To 10 mg of the freeze-dried powder was added 0.4 ml of aqueous solution of 5-fluorouracil (5-FU, 10 mg/ml) containing NaCl (0.05M) and/or CaCl2 (0.03M), and the mixture was allowed to stand for about an hour then warmed up and kept at 60° C. for 5 minutes. The mixture was allowed to stand at room temperature approximately for another 1 hour and mixed with 5 ml of isotonic aqueous NaCl. Thus obtained liposome dispersion was subjected to centrifugal separation (85,000 g×60 minutes). The precipitated liposomes were collected and dispersed in another 5 ml of isotonic NaCl solution, and isolated again by a centrifugal separator (85,000 g×60 minutes). Finally, thus isolated liposomes were broken by Triton X-100 whereby the released 5-FU was quantitatively analyzed by high performance liquid chromatography (column: Nucleosil 10 C18, solvent: 0.01M KH2 PO4).
TABLE 2______________________________________ Uptake rate (%) Captured Vol.*Ion of 5-FU (μl/mg lipid)______________________________________1 0.03 M CaCl2 31.3 12.52 0.05 M NaCl 22.6 9.03 0.05 M NaCl, 0.03 M CaCl2 32.7 13.1______________________________________
The results on Table 2 suggest that semi-synthetic phospholipids such as hydrogenated yolk lecithin, when the freeze-dried liposomes composed of them are regenerated, are reformed into liposomes having a large captured volume by the effect of calcium ion like as natural ones (yolk lecithin) or synthetic ones (DPPC).
In the same manner as in Example 1, MLV was prepared by use of dipalmitoyl phosphatidylcholine (DPPC) and freeze-dried. The freeze-dried MLV (10 mg each) was dispersed in an aqueous solution (0.4 ml) of 19 mM latamoxef containing 0.03M CaCl2 and in that not containing CaCl2. The two mixtures were respectively warmed up and kept at 50° C. for 5 minutes. The uptake rates of latamoxef and the captured volumes of the regenerated liposomes are shown in Table 3.
TABLE 3______________________________________ Uptake rate (%) Captured Vol.Ion of latamoxef (μl/mg lipid)______________________________________1 None 9.5 3.82 0.03 M CaCl2 36.5 14.6______________________________________
The freeze-dried MLV (10 mg each) composed of DPPC prepared in Example 3 was added to 0.4 ml each of 0.25% aqueous solution of 5-FU containing either one of the salts listed in Tables 4 to 7, and warmed up and kept at 50° C. for 5 minutes. The uptake rates of 5-FU and the captured volumes of the regenerated liposomes are shown in Tables 4 to 7.
TABLE 4______________________________________ Divalent Uptake CapturedMonovalent metallic ion rate Vol.cation CaCl2 (%) (μl/mg lipid)______________________________________1 0.05 M NaCl None 4.7 1.92 0.05 M NaCl 0.01 M 40.2 16.13 0.05 M NaCl 0.05 M 38.2 15.34 0.05 M CH3 COONa None 3.2 1.35 0.05 M CH3 COONa 0.05 M 40.5 16.26 0.05 M CH3 COONH4 None 3.2 1.37 0.05 M CH3 COONH4 0.05 M 27.2 10.9______________________________________
TABLE 5______________________________________Monovalent Divalent Uptake rate Captured Vol.cation metallic ion (%) (μl/mg lipid)______________________________________1 0.05 M NaCl None 4.7 1.92 0.05 M NaCl 0.01 M MgCl2 41.5 16.63 0.05 M NaCl 0.01 M MnCl2 40.7 16.34 0.05 M NaCl 0.05 M CoCl2 22.0 8.85 0.05 M NaCl 0.05 M ZnSo4 27.7 11.1______________________________________
TABLE 6______________________________________Concentration Uptake rate Captured Volumeof CaCl2 (%) (μl/mg lipid)______________________________________1 1.0 M 0.7 0.032 3.0 mM 45.9 18.43 0.5 mM 3.0 1.24 0.1 mM 43.9 17.6______________________________________
TABLE 7______________________________________Concentration Uptake rate Captured Volumeof MnCl2 (%) (μl/mg lipid)______________________________________1 0.2 M 11.0 4.42 5.0 mM 43.2 17.33 0.5 mM 4.8 1.94 0.2 mM 43.0 17.2______________________________________
The liposome compositions prepared by the present invention have a high uptake-rate and therefore entrap the aimed active ingredient therein in high efficiency. Since each regenerated liposome has a large captured volume, a large amount of the active ingredient is entrapped in it by a less amount of the phospholipid: this means that the liposome compositions keep such troubles away as toxicity accompanied by phospholipid when administered, or the like.
Additionally, both liposome and active ingredients can be stored in a stable state, because the active ingredient to be entrapped may be admixed at the time when the freeze-dried liposomes are regenerated.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US4310506 *||Feb 20, 1980||Jan 12, 1982||California Institute Of Technology||Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US4885172 *||Dec 15, 1986||Dec 5, 1989||The Liposome Company, Inc.||Composition for targeting, storing and loading of liposomes|
|US4921644 *||Feb 29, 1988||May 1, 1990||Technology Unlimited, Inc.||Mucin directed lipsome|
|US4950432 *||Oct 16, 1987||Aug 21, 1990||Board Of Regents, The University Of Texas System||Polyene microlide pre-liposomal powders|
|US4963297 *||Dec 22, 1987||Oct 16, 1990||The Liposome Company, Inc.||Spontaneous vesticulation of multilamellar liposomes|
|US5171578 *||Jun 6, 1991||Dec 15, 1992||The Liposome Company, Inc.||Composition for targeting, storing and loading of liposomes|
|US5178875 *||Jan 14, 1991||Jan 12, 1993||The Board Of Regents, The University Of Texas System||Liposomal-polyene preliposomal powder and method for its preparation|
|US5204112 *||Jun 12, 1987||Apr 20, 1993||The Liposome Company, Inc.||Induction of asymmetry in vesicles|
|US5227170 *||Jun 20, 1990||Jul 13, 1993||Vestar, Inc.||Encapsulation process|
|US5246707 *||Dec 3, 1991||Sep 21, 1993||Haynes Duncan H||Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes|
|US5252263 *||Mar 17, 1992||Oct 12, 1993||The Liposome Company, Inc.||Induction of asymmetry in vesicles|
|US5290563 *||Nov 26, 1991||Mar 1, 1994||Laboratoire Des Stallergenes||Method for combining a mixture of heterogeneous substances with liposomes|
|US5376452 *||Oct 6, 1993||Dec 27, 1994||The Liposome Company, Inc.||Induction of asymmetry in vesicles|
|US5501859 *||Mar 22, 1994||Mar 26, 1996||Walter T. Woods, Jr.||Absorbable magnesium composition and method of using same|
|US5503850 *||Dec 9, 1994||Apr 2, 1996||Research Corporation Technologies, Inc.||Method and composition for the treatment of thrombosis in a mammal|
|US5624673 *||Jun 4, 1992||Apr 29, 1997||Lymh Recherche||Cosmetic or pharmaceutical composition containing a prunella extract|
|US5665381 *||Jun 6, 1995||Sep 9, 1997||Nexstar Pharmaceuticals, Inc.||Inhibition of aggregation of drug containing particles|
|US5756120 *||Jun 6, 1995||May 26, 1998||Nexstar Pharmaceuticals, Inc.||Antibiotic formulation and use for drug resistant infections|
|US5756121 *||Jun 6, 1995||May 26, 1998||Nexstar Pharmaceuticals, Inc.||Antibiotic formulation and use for drug resistant infections|
|US5756122 *||Jun 7, 1995||May 26, 1998||Georgetown University||Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells|
|US5759571 *||May 11, 1993||Jun 2, 1998||Nexstar Pharmaceuticals, Inc.||Antibiotic formulation and use for drug resistant infections|
|US5830498 *||Sep 28, 1995||Nov 3, 1998||Board Of Regents, The University Of Texas System||Liposomal-polyene preliposomal powder and method for its preparation|
|US5916588 *||May 25, 1995||Jun 29, 1999||The Liposome Company, Inc.||Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use|
|US5958449 *||May 21, 1998||Sep 28, 1999||Nexstar Pharmaceuticals, Inc.||Antibiotic formulation and use for bacterial infections|
|US5965158 *||Nov 26, 1997||Oct 12, 1999||The University Of Texas System & Board Of Regents||Liposomal-polyene preliposomal powder and method for its preparation|
|US6090406 *||Feb 26, 1990||Jul 18, 2000||The Liposome Company, Inc.||Potentiation of immune responses with liposomal adjuvants|
|US6221388||Sep 28, 1999||Apr 24, 2001||Gilead Sciences, Inc.||Antibiotic formulation and use for bacterial infections|
|US6576264||Oct 17, 1996||Jun 10, 2003||Skyepharma Canada Inc.||Insoluble drug delivery|
|US6634576||Aug 29, 2001||Oct 21, 2003||Rtp Pharma Inc.||Milled particles|
|US6682761||Apr 20, 2001||Jan 27, 2004||Rtp Pharma, Inc.||Water-insoluble drug particle process|
|US6974593||Jun 9, 2003||Dec 13, 2005||Jagotec Ag||Insoluble drug delivery|
|US6979456||Mar 30, 1999||Dec 27, 2005||Jagotec Ag||Anticancer compositions|
|US7041705||Mar 26, 2001||May 9, 2006||Jagotec Ag||Injectable aqueous dispersions of propofol|
|US7097849||Aug 18, 1999||Aug 29, 2006||Jagotec Ag||Injectable aqueous dispersions of propofol|
|US7255877||Mar 31, 1999||Aug 14, 2007||Jagotec Ag||Fenofibrate microparticles|
|US7744921||Aug 20, 2007||Jun 29, 2010||Celator Pharmaceuticals, Inc.||Liposome loading with metal ions|
|US7939105||Nov 19, 1999||May 10, 2011||Jagotec Ag||Process for preparing a rapidly dispersing solid drug dosage form|
|US7939106||May 23, 2003||May 10, 2011||Jagotec Ag||Process for preparing a rapidly dispersing solid drug dosage form|
|US8206746||Sep 30, 2002||Jun 26, 2012||Jagotec Ag||Microparticles of water-insoluble substances|
|US8415329||May 28, 1999||Apr 9, 2013||Jagotec Ag||Thermoprotected compositions and process for terminal steam sterilization of microparticle preparations|
|US8586094||May 2, 2003||Nov 19, 2013||Jagotec Ag||Coated tablets|
|US8703202||Jul 24, 2006||Apr 22, 2014||Jagotec Ag||Coated tablets|
|US9468603 *||Sep 13, 2014||Oct 18, 2016||Arbor Therapeutics, LLC||Nanoparticulate compositions for targeted delivery of acid labile, lipophilic prodrugs of cancer chemotherapeutics and their preparation|
|US20020119199 *||Mar 31, 1999||Aug 29, 2002||Indu Parikh||Fenofibrate microparticles|
|US20030013693 *||Apr 22, 2002||Jan 16, 2003||Rtp Pharma Inc.||Method and composition for treatment of inflammatory conditions|
|US20030124180 *||May 2, 2001||Jul 3, 2003||Jurgen Ebert||Liposomes containing active substances|
|US20040018229 *||Jun 9, 2003||Jan 29, 2004||Henriksen Inge B.||Insoluble drug delivery|
|US20040086571 *||Mar 17, 2003||May 6, 2004||Skyepharma Canada Inc.||Fibrate-statin combinations with reduced fed-fasted effects|
|US20040138110 *||Jan 14, 2004||Jul 15, 2004||Wilex Ag||Inhibitors of the urokinase receptor|
|US20060193904 *||Oct 21, 2005||Aug 31, 2006||Paul Tardi||Liposome loading with metal ions|
|US20060210622 *||Nov 14, 2005||Sep 21, 2006||Skyepharma Canada Inc.||Surface modified particulate compositions of biologically active substances|
|US20080044464 *||Aug 20, 2007||Feb 21, 2008||Paul Tardi||Liposome loading with metal ions|
|US20100260830 *||Apr 7, 2010||Oct 14, 2010||Brian A Salvatore||Liposomal Formulations of Tocopheryl Amides|
|US20130330381 *||Jul 22, 2013||Dec 12, 2013||Transdermal Biotechnology, Inc.||Methods of delivering stable topical drug compositions|
|US20150079189 *||Sep 13, 2014||Mar 19, 2015||Arbor Therapeutics, LLC||Nanoparticulate Compositions for Targeted Delivery of Acid Labile, Lipophilic Prodrugs of Cancer Chemotherapeutics and Their Preparation|
|USRE35338 *||Sep 12, 1994||Sep 24, 1996||Pharma-Logic, Inc.||Sustained release delivery of water soluble bio-molecules and drugs using phosphokipid-coated microcrystals, microdroplets and high-concentration lipsomes|
|WO1989005149A1 *||Nov 30, 1988||Jun 15, 1989||The Liposome Company, Inc.||Methyl cellulose pharmaceutical composition|
|WO1989005151A1 *||Nov 30, 1988||Jun 15, 1989||The Liposome Company, Inc.||High integrity liposomes and method of preration and use|
|WO1989005636A1 *||Dec 22, 1988||Jun 29, 1989||The Liposome Company, Inc.||Spontaneous vesiculation of multilamellar liposomes|
|WO1989007937A1 *||Feb 24, 1989||Sep 8, 1989||Technology Unlimited, Inc.||Mucin directed liposome|
|WO1990015595A1 *||Jun 20, 1990||Dec 27, 1990||Vestar, Inc.||Encapsulation process|
|WO1996040062A1 *||Jun 6, 1996||Dec 19, 1996||Georgetown University||A method of transfection of cells using liposomally encapsulated nucleic acids|
|WO2001082892A2 *||May 2, 2001||Nov 8, 2001||Pharmacept Gmbh||Liposomes containing active substances|
|WO2001082892A3 *||May 2, 2001||Apr 15, 2004||Pharmacept Gmbh||Liposomes containing active substances|
|WO2009050333A1||Oct 14, 2008||Apr 23, 2009||Biomed Oy||Microencapsulated liposomal compositions|
|U.S. Classification||424/450, 424/417, 264/4.6, 264/4.1, 264/4.3, 428/402.2|
|International Classification||A61K9/00, A61K9/127|
|Cooperative Classification||A61K9/1277, Y10T428/2984|
|Sep 19, 1985||AS||Assignment|
Owner name: SHIONOGI & CO., LTD., FUKUSHIMA-KU, OSAKA, JAPAN
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:JIZOMOTO, HIROAKI;REEL/FRAME:004459/0497
Effective date: 19850809
|Feb 7, 1992||FPAY||Fee payment|
Year of fee payment: 4
|Sep 27, 1995||FPAY||Fee payment|
Year of fee payment: 8
|Feb 29, 2000||REMI||Maintenance fee reminder mailed|
|Aug 6, 2000||LAPS||Lapse for failure to pay maintenance fees|
|Oct 10, 2000||FP||Expired due to failure to pay maintenance fee|
Effective date: 20000809